Immitra Bio Secures €2.58 Mn Pre-Seed Round for Next-Generation Gene Editing Platform

Out of the total funding, €2.42 million (CHF 2.25 million) came from venture capital firms and private investors. The company also received €161.8k (CHF 150k) in non-dilutive funding, which means it did not have to give up company ownership for that money.

The funding round was led by Backbone Ventures and co-led by OCCIDENT. Other investors included Another VC, Kickfund, Venture Kick, Zürcher Kantonalbank, FONGIT, ETH Foundation, and several private investors.

Jan Nelis, CEO and co-founder of Immitra Bio, said, “At Immitra Bio, we are advancing a fundamentally new approach to gene editing therapies and are proud to be backed by a syndicate of early-stage and life science specialist investors. This pre-seed financing enables important value inflection points for the company and lays the foundation for establishing Immitra Bio as a leader in in-vivo gene editing. Our goal is to make gene editing therapies scalable, commercially viable, and accessible to patients. Our platform has the potential to generate dozens of highly differentiated therapeutic assets in an accelerated fashion.”

Paul Sunzenauer from OCCIDENT said, “Recent advances and growing market adoption of gene therapies have validated the enormous potential of curative genetic medicine. However, current approaches still face significant challenges, such as chemotherapy-related toxicities, manufacturing complexity, and limited scalability.

“Immitra Bio’s differentiated in-vivo platform is designed to address these challenges head-on. We believe that combining non-viral delivery with a mutation-independent therapeutic approach has the potential to transform the treatment of genetic diseases and make curative therapies accessible to a much larger patient population. We are impressed by the team’s bold vision and scientific excellence and we are excited to support Immitra Bio in advancing the next generation of genetic medicines.”

Founded in 2024 by Nelis, Amir Taheri, and Jacob Corn, Immitra Bio is building a platform to develop one-time gene-editing treatments that could permanently treat genetic diseases. The company uses a new gene-editing technology along with a digital platform to identify the right treatment targets.

Its technology is designed to work for a wide range of genetic mutations, making it easier to create treatments for more patients. The company aims to make gene-editing therapies more scalable and widely available.

Immitra Bio says its approach avoids many of the challenges of current gene-editing treatments, such as complex cell processing outside the body, intensive patient preparation, stem cell transplants, and personalized therapies. This could make future treatments simpler, faster, and more accessible.

Read Also- Ossprey Secures US$2.65 Million Pre-Seed to Protect Open-Source Software